Clinical Trial Update: Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial update of a second autologous stem cell transplant regimen using Elo-Pom-Dex for relapsed multiple myeloma; results were posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Elotuzumab (elotuzumab)
• Pomalidomide (Pomalidomide)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Multiple Myeloma in Relapse | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-12-15